Clairity

A Novel Platform for Prediction Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer, using only her existing screening mammogram. Current Screening Detects Cancer Only After It Appears Until now, screeni

Clairity seeks mission-driven, thoughtful, motivated team members and is committed to mentoring and developing its employees while giving them autonomy and responsibility.

Joe Cunningham, MD Board of Directors Managing Director, Santé Ventures BACK TO TEAM Joe co-founded Santé Ventures in 2006 and is nationally recognized for his expertise across healthcare delivery systems, physician associations a

Kevin Lalande Co-Founder, Board of Directors Managing Director, Santé Ventures BACK TO TEAM Kevin M. Lalande is Founding Managing Director and Chief Investment Officer of Santé, an investment partnership with $1 billion in capital

Leadership The Clairity team brings with it extensive clinical and health technology experience, along with decades focused on improving the lives of others. Connie Lehman, MD, PhDFounder & CEO Joan MalcolmChief Commercial Officer Jenna BartonVice President of Fi

Clairity’s mission is to shift cancer care from reactive diagnosis to proactive prevention by identifying future risk, cultivating trust, and saving lives. The company believes everyone deserves to understand their health risks, regardless of race.

Clairity Breast is an FDA-authorized AI platform that predicts a woman’s five-year risk of developing breast cancer using her existing screening mammogram.

Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer, using only her existing screening mammogram.

Clairity announces that updated NCCN guidelines include an AI mammogram-based tool to assess future breast cancer risk. The tool provides a five-year risk assessment and identifies women at increased risk beginning at age 35, including women whom traditional methods miss.

Apr 2026 · GlobeNewswireNews article

Clairity’s FDA-authorized Clairity Breast tool has delivered its first cancer risk score to a clinical patient. The image-based AI tool assesses a woman’s future breast cancer risk from a screening mammogram, and the first administration marks a historic milestone in women’s health.

Feb 2026 · GlobeNewswireNews article

Clairity founder and CEO Dr. Connie Lehman is named to TIME’s 2026 TIME100 Health list. The list recognizes 100 of the world’s most influential health leaders, and Lehman is recognized for advancing AI-driven breast cancer risk assessment.

Feb 2026 · GlobeNewswireNews article

Clairity appoints founder Dr. Connie Lehman as chief executive officer as the company enters clinical adoption and growth. Joe Kiani is named chairman of the board of directors.

Jan 2026 · GlobeNewswireNews article